Illumina Secures CMS Reimbursement for TruSight Oncology Comprehensive Test at $2,989.55
核心洞察
The Centers for Medicare and Medicaid Services (搜索) has approved reimbursement for Illumina's FDA-approved TruSight Oncology Comprehensive (搜索) test at $2,989.55 per test, effective January 1, 2026.
The comprehensive genomic profiling test analyzes over 500 genes to identify cancer biomarkers and guide targeted therapy selection for solid tumor patients.
This reimbursement decision removes barriers to comprehensive genomic profiling adoption and enables laboratories of all sizes to deliver precision oncology diagnostics closer to the point of care.
Illumina announced that the Centers for Medicare and Medicaid Services (搜索) (CMS) has granted reimbursement for its FDA-approved TruSight Oncology (TSO) Comprehensive test, marking a significant milestone for precision oncology access in the United States. The comprehensive genomic profiling test will be reimbursed at $2,989.55 per test under the Clinical Laboratory Fee Schedule, effective January 1, 2026.
Expanding Access to Precision Oncology
The reimbursement decision addresses a critical barrier that has limited the adoption of comprehensive genomic profiling for cancer patients. "This decision helps removes barriers that have limited adoption of comprehensive genomic profiling for patients, empowering more healthcare providers to deliver precision oncology insights that will improve outcomes," said John Fox, MD, senior director, Market Access and Government Affairs at Illumina.
TSO Comprehensive enables clinicians to simultaneously assess hundreds of genes, including relevant cancer biomarkers, to inform treatment decisions. The test interrogates more than 500 genes to profile a patient's solid tumor, helping increase the likelihood of identifying immuno-oncology or other clinically actionable biomarkers that can guide targeted therapy selection or clinical trial enrollment.
Clinical Implementation and Laboratory Access
The reimbursement pathway uses Proprietary Laboratory Analysis (PLA) code 0543U, establishing a clear and predictable reimbursement framework for all Medicare beneficiaries. This development enables laboratories of all sizes to deliver FDA-approved, clinically valuable genomic insights that are easy to access and implement, promoting broader access to precision oncology diagnostics across academic medical centers, healthcare networks, hospitals, and regional reference laboratories.
With reimbursement now in place, more laboratories will be able to bring comprehensive genomic profiling in-house and deliver clinically actionable results to their patients, closer to the point of care. TSO Comprehensive enables laboratories of all sizes to deliver FDA-approved, clinically valuable genomic insights across diverse healthcare settings.
Companion Diagnostic Applications
TSO Comprehensive serves as an approved companion diagnostic for specific targeted therapies. The test is approved to identify adult and pediatric patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (搜索) (NTRK (搜索)) gene fusions and may benefit from treatment with Bayer's VITRAKVI (larotrectinib). Additionally, the test identifies adult patients with locally advanced or metastatic rearranged-during-transfection (RET (搜索)) fusion-positive non-small-cell lung cancer (NSCLC) who may benefit from treatment with Lilly (搜索)'s RETEVMO (selpercatinib).
Market Growth and Clinical Demand
Clinical demand for genomic testing is growing at every level of the healthcare ecosystem, creating opportunities for better healthcare and improved quality of life through advanced diagnostic access. Illumina reported that clinical markets served as a key driver of growth, with roughly 60% of the company's sequencing consumables revenue driven by clinical customers in 2025.
The reimbursement decision reflects the expanding role of personalized genomics in oncology care and the healthcare system's recognition of comprehensive genomic profiling's clinical value in guiding precision medicine approaches for cancer treatment.